Cell and gene therapies are altering the treatment landscape of intractable genetic disorders, including cancer and inherited diseases.
Single-cell DNA sequencing on the Tapestri Platform provides several advantages over other currently used techniques which require clonal outgrowth followed by qPCR to assess DNA integrations in cell and gene therapy workflows. Relative to qPCR, single-cell sequencing reduces the time to testing results by weeks. In addition, single-cell sequencing quantifies the presence or absence of DNA integrations, including transductions, without the need for lengthy cell culture protocols.
The Tapestri Platform provides an unprecedented level of quantification of DNA integrations in significantly less time compared to bulk approaches and does so at single cell resolution. These characteristics allow for the rapid optimization of transduction protocols or HDR protocols during therapy development and streamlined testing and release of transduced or integrated cells during manufacturing of therapeutic products.
Offered Free by: MissionBio
See All Resources from: MissionBio